This is a quite sensitive topic for Inderes, easily flagged or otherwise removed, but these matters must be allowed to be brought to light within the framework of Finnish law. I am not blaming anyone, but I am issuing a challenge. Antti, have you considered that if Bex were suitable for Faron’s estimated 20-30% of all cancers, it would mean annual sales of 60-90 billion euros? Assuming 20% royalties, that would be 12-18 billion annually; then a 30% market share of that would be 3.6–5.4 billion every year, and applying a success probability of 10% (pulled out of a hat) means 360–540 million every year. Applying the Hex average P/E of 17 would then mean an average company valuation of approximately 7.65 billion, which, with the current share count including a possible rights issue, is €38.75 per share. I am a mathematician; tell me where our 50x difference in vision lies, thank you. My target price with the aforementioned calculations is not for 12 months, but for 3–5 years out.
2 Likes